Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 6/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24340204 | 1.00 | EPHX2 (0.48) | EPHX2BRD4BRD2BRD3BRDT | |
| SCHEMBL7886607 | 0.91 | — | — | |
| SCHEMBL23299889 | 0.87 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL23299890 | 0.87 | EPHX2 (0.35) | EPHX2 | |
| SCHEMBL4103966 | 0.81 | SIGMAR1 (0.43) | EPHX2SMN1; SMN2 | |
| SCHEMBL26044029 | 0.81 | — | — | |
| SCHEMBL23153441 | 0.80 | SMYD3 (0.39) | F2ST14 | |
| SCHEMBL20445357 | 0.80 | SMYD3 (0.39) | F2ST14 | |
| SCHEMBL4100399 | 0.79 | SIGMAR1 (0.46) | EPHX2SMN1; SMN2 | |
| Iodide SCHEMBL27688322 | 0.77 | SIGMAR1 (0.45) | EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | EPHX2 2228/4885BRD4 302/4885BRD2 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.